

Global Non-Invasive Liquid Biopsy Market: Focus on Offering, Sample, Application, Technology, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

<https://marketpublishers.com/r/GEE644E307D4EN.html>

Date: August 2021

Pages: 249

Price: US\$ 5,250.00 (Single User License)

ID: GEE644E307D4EN

Abstracts

Market Report Coverage - Non-Invasive Liquid Biopsy

Market Segmentation

Offering– Products (Kits and Assays) and Services

Sample – Stool, Urine, Saliva, and Other Samples

Application – Oncology, Reproductive Health, Metabolic Disorders, and Other Applications

Technology – Polymerase Chain Reaction (RT-PCR and dPCR), Sequencing (NGS and Sanger Sequencing), Microarray, and Other Technologies

End User – Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Other End Users

Regional Segmentation

North America – U.S., and Canada

Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe

Asia-Pacific – China, Japan, India, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific

Latin America – Brazil, Mexico, and Rest-of-Latin America

Rest-of-the-World

Market Growth Drivers

Global Increase in Cancer Prevalence

Increasing Government Funding for Healthcare

Rise in Patient Preference for Non-Invasive Cancer Diagnosis

Growing Prominence of Precision Medicine in the Oncology Ecosystem

Market Challenges

False Negatives and Positives

Lack of Favorable Reimbursement Policies

Existing Diagnostic Confidence on Conventional Tissue-Based Biopsies

Market Opportunities

Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy

Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging Markets

Key Companies Profiled

Bio-Techne Corporation, Endress + Hauser Group, Exact Sciences Corporation, Lonza Group AG, MDxHealth, Merck KGaA, MutantDx, Norgen Biotek Corp, Nucleix Ltd., Oasis Diagnostics Corporation, OraSure Technologies, Inc., PerkinElmer Inc., Predicine, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Zymo Research Corporation

Key Questions Answered in this Report:

How is non-invasive liquid biopsy revolutionizing the field of oncology, reproductive health, and metabolic disorders?

What are the major market drivers, challenges, and opportunities in the global non-invasive liquid biopsy market?

What are the underlying structures resulting in the emerging trends within the global non-invasive liquid biopsy market?

How did the COVID-19 pandemic impact the global non-invasive liquid biopsy ecosystem?

What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?

What are the key regulatory implications in developed and developing regions pertaining to the use of non-invasive liquid biopsy?

What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?

How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:

Offering (products and services)

Sample (stool, urine, saliva, and other samples)

Technology (sequencing, polymerase chain reaction (PCR), microarray, and other technologies)

Application (oncology, reproductive health, metabolic disorders, and other applications)

End User (academic and research institutions, hospitals and diagnostic laboratories, and other end users)

Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)

What are the growth opportunities for the non-invasive liquid biopsy companies in the region of their operation?

Who are the leading players with significant offerings in the global non-invasive liquid biopsy market?

Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Our healthcare experts have found the non-invasive liquid biopsy industry to be one of the most rapidly evolving and dynamic markets, and the global market for non-invasive liquid biopsy is predicted to grow at a CAGR of 20.38% over the forecast period 2021-2031. The market is driven by certain factors, which include a global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem.

The market is favored by the developments in the field of cancer molecular diagnostic testing and its attributes such as non-invasive liquid biopsy. Currently, the non-invasive liquid biopsy industry is witnessing an upsurge due to the global increase in cancer prevalence, increasing government funding for healthcare, rise in patient preference for non-invasive cancer diagnosis, and growing prominence of precision medicine in the oncology ecosystem.

Furthermore, biotechnology companies are focusing on the development of robust non-invasive liquid biopsy solutions for a wide range of applications, including oncology, reproductive health, metabolic disorders, to support clinicians to unravel insights

pertaining to the analysis of genetic alterations present in the circulating biomarkers in samples such as stool, urine, and saliva. The development of non-invasive liquid biopsy products and services enabled clinicians to offer early cancer screening and diagnosis to patients, further improving survival rates.

Within the research report, the market is segmented on the basis of offering, sample, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of cases associated with cancer has created a buzz among the biotechnology companies to further invest in the development of innovative cancer diagnostics, including non-invasive liquid biopsy, further aiding physicians to offer value-based clinical outcomes to patients. Due to the established presence of Exact Sciences Corporation in the U.S. market, offering its proprietary Cologuard test, the company has been the leading player in the non-invasive liquid biopsy ecosystem.

On the basis of region, North America holds the largest share of the non-invasive liquid biopsy market due to high infusion of funding from the government organizations for conducting cancer research, increasing prevalence of cancer, presence of market juggernauts in the region, growing awareness about non-invasive liquid biopsy products, and increasing awareness about early cancer screening. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.

Contents

1 PRODUCT DEFINITION

1.1 Inclusion and Exclusion

2 MARKET SCOPE

2.1 Scope of the Study

2.2 Key Questions Answered in the Report

3 RESEARCH METHODOLOGY

3.1 Global Non-Invasive Liquid Biopsy Market: Research Methodology

3.2 Data Sources

3.2.1 Primary Data Sources

3.2.2 Secondary Data Sources

3.3 Market Estimation Model

3.4 Criteria for Company Profiling

4 MARKET OVERVIEW

4.1 Market Definition

4.2 Emerging Applications of Non-Invasive Liquid Biopsy

4.3 Market Footprint and Growth Potential, \$Million, 2020-2031

4.4 COVID-19 Impact on the Global Non-Invasive Liquid Biopsy Market

5 INDUSTRY ANALYSIS

5.1 Overview

5.2 Legal Requirements and Framework in the U.S.

5.2.1 FDA Regulation

5.2.2 CMS Regulation

5.3 Legal Requirements and Frameworks in Europe

5.4 Legal Requirements and Frameworks in Asia-Pacific

5.4.1 China

5.4.2 Japan

5.5 Reimbursement Analysis

5.6 Return on Investment (RoI) Analysis

6 MARKET DYNAMICS

6.1 Overview

6.2 Impact Analysis

6.3 Market Drivers

6.3.1 Global Increase in Cancer Prevalence

6.3.2 Increasing Government Funding for Healthcare

6.3.3 Rise in Patient Preference for Non-Invasive Cancer Diagnosis

6.3.4 Growing Prominence of Precision Medicine in the Oncology Ecosystem

6.4 Market Restraints

6.4.1 False Negatives and Positives

6.4.2 Lack of Favorable Reimbursement Policies

6.4.3 Existing Diagnostic Confidence on Conventional Tissue-Based Biopsies

6.5 Market Opportunities

6.5.1 Amalgamation of Artificial Intelligence (AI) with Non-Invasive Liquid Biopsy

6.5.2 Massive Scope for the Adoption of Non-Invasive Liquid Biopsy Tests in the Emerging Markets

7 COMPETITIVE LANDSCAPE

7.1 Synergistic Activities

7.2 Product Approvals

7.3 Product Launches

7.4 Acquisitions

7.5 Funding and Other Activities

7.6 Market Share Analysis, 2019-2020

7.7 Growth-Share Analysis

7.7.1 Growth-Share Analysis (by Company)

7.7.2 Growth-Share Analysis (by Technology)

7.7.3 Growth-Share Analysis (by Application)

7.8 Pricing Analysis

7.8.1 Price with Sample Type

8 GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET (BY OFFERING), \$MILLION, 2020-2031

8.1 Overview

8.2 Offering

- 8.2.1 Kits
- 8.2.2 Assays
- 8.3 Services

9 GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET (BY SAMPLE), \$MILLION, 2021-2031

- 9.1 Overview
- 9.2 Stool
- 9.3 Urine
- 9.4 Saliva
- 9.5 Other Samples

10 GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET (BY APPLICATION), \$MILLION, 2020-2031

- 10.1 Overview
- 10.2 Oncology
- 10.3 Reproductive Health
- 10.4 Metabolic Disorders
- 10.5 Other Applications

11 GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET (BY TECHNOLOGY), \$MILLION, 2020-2031

- 11.1 Overview
- 11.2 Polymerase Chain Reaction (PCR)
 - 11.2.1 Real-Time PCR (RT-PCR)
 - 11.2.2 Digital PCR (dPCR)
- 11.3 Sequencing
 - 11.3.1 Next-Generation Sequencing (NGS)
 - 11.3.2 Sanger Sequencing
- 11.4 Microarray
- 11.5 Other Technologies

12 GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET (BY END USER), \$MILLION, 2020-2031

- 12.1 Overview

- 12.2 Hospitals and Diagnostic Laboratories
- 12.3 Academic and Research Institutions
- 12.4 Other End Users

13 GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET (BY REGION), \$MILLION, 2020-2031

- 13.1 Overview
- 13.2 North America
 - 13.2.1 U.S.
 - 13.2.2 Canada
 - 13.2.3 North America Non-Invasive Liquid Biopsy Market (by Application)
- 13.3 Europe
 - 13.3.1 Germany
 - 13.3.2 U.K.
 - 13.3.3 France
 - 13.3.4 Italy
 - 13.3.5 Spain
 - 13.3.6 Netherlands
 - 13.3.7 Rest-of-Europe
 - 13.3.8 Europe Non-Invasive Liquid Biopsy Market (by Application)
- 13.4 Asia-Pacific (APAC)
 - 13.4.1 China
 - 13.4.2 Japan
 - 13.4.3 India
 - 13.4.4 South Korea
 - 13.4.5 Australia
 - 13.4.6 Singapore
 - 13.4.7 Rest-of-Asia-Pacific (RoAPAC)
 - 13.4.8 Asia-Pacific Non-Invasive Liquid Biopsy Market (by Application)
- 13.5 Latin America (LATAM)
 - 13.5.1 Brazil
 - 13.5.2 Mexico
 - 13.5.3 Rest-of-Latin America (RoLA)
 - 13.5.4 Latin America Non-Invasive Liquid Biopsy Market (by Application)
- 13.6 Rest-of-the-World
 - 13.6.1 Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application)

14 COMPANY PROFILES

14.1 Overview

14.2 Bio-Techne Corporation

14.2.1 Company Overview

14.2.2 Role of Bio-Techne Corporation in the Global Non-Invasive Liquid Biopsy

Market

14.2.3 Financials

14.2.4 Key Insights About Financial Health of the Company

14.2.5 SWOT Analysis

14.3 Endress + Hauser Group

14.3.1 Company Overview

14.3.2 Role of Endress + Hauser Group in the Global Non-Invasive Liquid Biopsy

Market

14.3.3 Financials

14.3.4 Key Insights About Financial Health of the Company

14.3.5 SWOT Analysis

14.4 Exact Sciences Corporation

14.4.1 Company Overview

14.4.2 Role of Exact Sciences Corporation in the Global Non-invasive Liquid Biopsy

Market

14.4.3 Financials

14.4.4 Key Insights About Financial Health of the Company

14.4.5 SWOT Analysis

14.5 Lonza Group AG

14.5.1 Company Overview

14.5.2 Role of Lonza Group AG in the Global Non-Invasive Liquid Biopsy Market

14.5.3 Financials

14.5.4 Key Insights About Financial Health of the Company

14.5.5 SWOT Analysis

14.6 MDxHealth

14.6.1 Company Overview

14.6.2 Role of MDxHealth in the Global Non-Invasive Liquid Biopsy Market

14.6.3 Financials

14.6.4 Key Insights About Financial Health of the Company

14.6.5 SWOT Analysis

14.7 Merck KGaA

14.7.1 Company Overview

14.7.2 Role of Merck KGaA in the Global Non-Invasive Liquid Biopsy Market

14.7.3 Financials

- 14.7.4 Key Insights About Financial Health of the Company
- 14.7.5 SWOT Analysis
- 14.8 MutantDx
 - 14.8.1 Company Overview
 - 14.8.2 Role of MutantDx in the Global Non-Invasive Liquid Biopsy Market
 - 14.8.3 SWOT Analysis
- 14.9 Norgen Biotek Corp
 - 14.9.1 Company Overview
 - 14.9.2 Role of Norgen Biotek Corp in the Global Non-Invasive Liquid Biopsy Market
 - 14.9.3 SWOT Analysis
- 14.1 Nucleix Ltd.
 - 14.10.1 Company Overview
 - 14.10.2 Role of Nucleix Ltd. in the Global Non-Invasive Liquid Biopsy Market
 - 14.10.3 SWOT Analysis
- 14.11 Oasis Diagnostics Corporation
 - 14.11.1 Company Overview
 - 14.11.2 Role of Oasis Diagnostics Corporation in the Global Non-Invasive Liquid Biopsy Market
 - 14.11.3 SWOT Analysis
- 14.12 OraSure Technologies, Inc.
 - 14.12.1 Company Overview
 - 14.12.2 Role of OraSure Technologies, Inc. in the Global Non-Invasive Liquid Biopsy Market
 - 14.12.3 Financials
 - 14.12.4 Key Insights About Financial of the Company
 - 14.12.5 SWOT Analysis
- 14.13 PerkinElmer Inc.
 - 14.13.1 Company Overview
 - 14.13.2 Role of PerkinElmer Inc. in the Global Non-Invasive Liquid Biopsy Market
 - 14.13.3 Financials
 - 14.13.4 Key Insights About Financial Health of the Company
 - 14.13.5 SWOT Analysis
- 14.14 Predicine, Inc.
 - 14.14.1 Company Overview
 - 14.14.2 Role of Predicine, Inc. in the Global Non-Invasive Liquid Biopsy Market
 - 14.14.3 SWOT Analysis
- 14.15 QIAGEN N.V.
 - 14.15.1 Company Overview
 - 14.15.2 Role of QIAGEN N.V. in the Global Non-Invasive Liquid Biopsy Market

14.15.3 Financials

14.15.4 Key Insights About Financial Health of the Company

14.15.5 SWOT Analysis

14.16 Thermo Fisher Scientific Inc.

14.16.1 Company Overview

14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Non-Invasive Liquid Biopsy

Market

14.16.3 Financials

14.16.4 Key Insights About Financial Health of the Company

14.16.5 SWOT Analysis

14.17 Zymo Research Corporation

14.17.1 Company Overview

14.17.2 Role of Zymo Research Corporation in the Global Non-Invasive Liquid Biopsy

Market

14.17.3 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 5.1: Classification Rules of IVDs under the IVDR

Table 5.2: Key Coverage Providers for Non-Invasive Liquid Biopsy Tests

Table 6.1: Likert Scale

Table 6.2: Impact Analysis of Market Drivers

Table 6.3: Impact Analysis of Market Restraints

List Of Figures

LIST OF FIGURES

- Figure 1: U.S. National Cancer Institute (NCI), Fiscal Budget Year-on-Year, 2013-2018
- Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Non-Invasive Liquid Biopsy Market
- Figure 3: Global Non-Invasive Liquid Biopsy Market (by Offering), \$Million, 2020 and 2031
- Figure 4: Global Non-Invasive Liquid Biopsy Market (by Sample), \$Million, 2020 and 2031
- Figure 5: Global Non-Invasive Liquid Biopsy Market (by Application), \$Million, 2020 and 2031
- Figure 6: Global Non-Invasive Liquid Biopsy Market (by Technology), \$Million, 2020 and 2031
- Figure 7: Global Non-Invasive Liquid Biopsy Market (by End User), \$Million, 2020 and 2031
- Figure 8: Global Non-invasive Liquid Biopsy Market Snapshot
- Figure 2.1: Global Non-Invasive Liquid Biopsy Market Segmentation
- Figure 3.1: Global Non-Invasive Liquid Biopsy Market: Research Methodology
- Figure 3.2: Primary Research Methodology
- Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
- Figure 4.1: Global Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031
- Figure 4.2: Global Non-Invasive Liquid Biopsy Market: COVID-19 Impact Analysis
- Figure 5.1: Components Considered for Clinical Evidence as per the IVDR
- Figure 5.2: Global Non-Invasive Liquid Biopsy Market (Return on Investment (RoI) Analysis)
- Figure 6.1: Global Cancer Burden (by Region), 2018
- Figure 6.2: Increasing Government Spending for Healthcare, 2017
- Figure 7.1: Share of Key Developments and Strategies, January 2017–July 2021
- Figure 7.2: Share of Synergistic Activities (by Company), January 2017-June 2021
- Figure 7.3: Share of Product Approvals (by Company), January 2017-July 2021
- Figure 7.4: Number of Product Launches (by Company), January 2017–July 2021
- Figure 7.5: Share of Acquisitions (by Company), January 2017-July 2021
- Figure 7.6: Market Share Analysis for Global Non-Invasive Liquid Biopsy Market, \$Million, 2019 and 2020
- Figure 7.7: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Company), 2020

Figure 7.8: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Technology), 2020-2031

Figure 7.9: Growth-Share Analysis for Global Non-Invasive Liquid Biopsy Market (by Application), 2020-2031

Figure 8.1: Global Non-Invasive Liquid Biopsy Market (by Offering)

Figure 8.2: Global Non-Invasive Liquid Biopsy Market (by Offering), \$Million, 2020 and 2031

Figure 8.3: Global Non-Invasive Liquid Biopsy Market (by Offering), \$Million, 2020-2031

Figure 8.4: Global Non-Invasive Liquid Biopsy Market (by Offering), 2020 and 2031

Figure 8.5: Global Non-Invasive Liquid Biopsy Market (Kits), \$Million, 2020-2031

Figure 8.6: Global Non-Invasive Liquid Biopsy Market (Assays), \$Million, 2020-2031

Figure 8.7: Global Non-Invasive Liquid Biopsy Market (Services), \$Million, 2020-2031

Figure 9.1: Global Non-Invasive Liquid Biopsy Market (by Sample), \$Million, 2020-2031

Figure 9.2: Global Non-Invasive Liquid Biopsy Market (by Sample), 2020 and 2031

Figure 9.3: Global Non-Invasive Liquid Biopsy Market (Stool), \$Million, 2020-2031

Figure 9.4: Global Non-Invasive Liquid Biopsy Market (Urine), \$Million, 2020-2031

Figure 9.5: Global Non-Invasive Liquid Biopsy Market (Saliva), \$Million, 2020-2031

Figure 9.6: Global Non-Invasive Liquid Biopsy Market (Other Samples), \$Million, 2020-2031

Figure 10.1: Global Non-Invasive Liquid Biopsy Market (by Application)

Figure 10.2: Global Non-Invasive Liquid Biopsy Market (by Application), \$Million, 2020-2031

Figure 10.3: Global Non-Invasive Liquid Biopsy Market (Oncology), \$Million, 2020-2031

Figure 10.4: Global Non-Invasive Liquid Biopsy Market (Reproductive Health), \$Million, 2020-2031

Figure 10.5: Global Non-Invasive Liquid Biopsy Market (Metabolic Disorders), \$Million, 2020-2031

Figure 10.6: Global Non-Invasive Liquid Biopsy Market (Other Applications), \$Million, 2020-2031

Figure 11.1: Global Non-Invasive Liquid Biopsy Market (by Technology)

Figure 11.2: Global Non-Invasive Liquid Biopsy Market (by Technology), 2020 and 2031

Figure 11.3: Global Non-Invasive Liquid Biopsy Market (PCR), \$Million, 2020-2031

Figure 11.4: Global Non-Invasive Liquid Biopsy Market (PCR), 2020 and 2031

Figure 11.5: Global Non-Invasive Liquid Biopsy Market (RT-PCR, by PCR), \$Million, 2020-2031

Figure 11.6: Global Non-Invasive Liquid Biopsy Market (dPCR, by PCR), \$Million, 2020-2031

Figure 11.7: Global Non-Invasive Liquid Biopsy Market (Sequencing), \$Million, 2020-2031

Figure 11.8: Global Non-Invasive Liquid Biopsy Market (Sequencing), 2020 and 2031

Figure 11.9: Global Non-Invasive Liquid Biopsy Market (NGS, by Sequencing), \$Million, 2020-2031

Figure 11.10: Global Non-Invasive Liquid Biopsy Market (Sanger Sequencing, by Sequencing), \$Million, 2020-2031

Figure 11.11: Global Non-Invasive Liquid Biopsy Market (Microarray), \$Million, 2020-2031

Figure 11.12: Global Non-Invasive Liquid Biopsy Market (Other Technologies), \$Million, 2020-2031

Figure 12.1: Global Non-Invasive Liquid Biopsy Market (by End User)

Figure 12.2: Global Non-Invasive Liquid Biopsy Market (by End User), \$Million, 2020-2031

Figure 12.3: Global Non-Invasive Liquid Biopsy Market (Hospitals and Diagnostic Laboratories), \$Million, 2020-2031

Figure 12.4: Global Non-Invasive Liquid Biopsy Market (Academic and Research Institutions), \$Million, 2020-2031

Figure 12.5: Global Non-Invasive Liquid Biopsy Market (Other End Users), \$Million, 2020-2031

Figure 13.1: Global Non-Invasive Liquid Biopsy Market (by Region): Market Snapshot

Figure 13.2: Global Non-Invasive Liquid Biopsy Market (by Region), \$Million, 2020-2031

Figure 13.3: North America Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.4: North America: Market Dynamics

Figure 13.5: North America Non-Invasive Liquid Biopsy Market (by Country), \$Million, 2020-2031

Figure 13.6: U.S. Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.7: Canada Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.8: North America Non-Invasive Liquid Biopsy Market (by Application), \$Million, 2020-2031

Figure 13.9: Europe Non-invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.10: Europe: Market Dynamics

Figure 13.11: Europe Non-Invasive Liquid Biopsy Market (by Country), \$Million, 2020-2031

Figure 13.12: Germany Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.13: U.K. Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.14: France Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.15: Italy Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.16: Spain Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.17: Netherlands Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.18: Rest-of-Europe Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.19: Europe Non-Invasive Liquid Biopsy Market (by Application), \$Million, 2020-2031

Figure 13.20: Asia-Pacific Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.21: APAC Non-Invasive Liquid Biopsy Market (by Country), \$Million, 2020-2031

Figure 13.22: China Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.23: Japan Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.24: India Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.25: South Korea Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.26: Australia Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.27: Singapore Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.28: RoAPAC Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.29: APAC Non-Invasive Liquid Biopsy Market (by Application), \$Million, 2020-2031

Figure 13.30: Latin America Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.31: Latin America: Market Dynamics

Figure 13.32: Latin America Non-Invasive Liquid Biopsy Market (by Country), \$Million, 2020-2031

Figure 13.33: Brazil Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.34: Mexico Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.35: RoLA Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.36: LATAM Non-Invasive Liquid Biopsy Market (by Application), \$Million, 2020-2031

Figure 13.37: Rest-of-the-World Non-Invasive Liquid Biopsy Market, \$Million, 2020-2031

Figure 13.38: Rest-of-the-World Non-Invasive Liquid Biopsy Market (by Application), \$Million, 2020-2031

Figure 14.1: Total Number of Companies Profiled

Figure 14.2: Bio-Techne Corporation: Service Portfolio

Figure 14.3: Bio-Techne Corporation: Overall Financials, 2018-2020

Figure 14.4: Bio-Techne Corporation: Revenue (by Segment), 2018-2020

Figure 14.5: Bio-Techne Corporation: Revenue (by Region), 2018-2020

Figure 14.6: Bio-Techne Corporation: R&D Expenditure, 2018-2020

Figure 14.7: Bio-Techne Corporation: SWOT Analysis

Figure 14.8: Endress + Hauser Group: Product Portfolio

Figure 14.9: Endress + Hauser Group: Overall Financials, 2018-2020

Figure 14.10: Endress + Hauser Group: Revenue (by Segment), 2018-2020

Figure 14.11: Endress + Hauser Group: Revenue (by Region), 2018-2020

Figure 14.12: Endress + Hauser Group: R&D Expenditure, 2018-2020

- Figure 14.13: Endress + Hauser Group: SWOT Analysis
- Figure 14.14: Exact Sciences Corporation: Service Portfolio
- Figure 14.15: Exact Sciences Corporation: Overall Financials, 2018-2020
- Figure 14.16: Exact Sciences Corporation: Revenue (by Segment), 2018-2020
- Figure 14.17: Exact Sciences Corporation: Revenue (by Region), 2018-2020
- Figure 14.18: Exact Sciences Corporation: R&D Expenditure, 2018-2020
- Figure 14.19: Exact Sciences Corporation: SWOT Analysis
- Figure 14.20: Lonza Group AG: Product Portfolio
- Figure 14.21: Lonza Group AG: Overall Financials, 2018-2020
- Figure 14.22: Lonza Group AG: Revenue (by Segment), 2018-2020
- Figure 14.23: Lonza Group AG: Revenue (by Region), 2018-2020
- Figure 14.24: Lonza Group AG: R&D Expenditure, 2018-2020
- Figure 14.25: Lonza Group AG: SWOT Analysis
- Figure 14.26: MDxHealth: Service Portfolio
- Figure 14.27: MDxHealth: Overall Financials, 2018-2020
- Figure 14.28: MDxHealth: Revenue (by Segment), 2018-2020
- Figure 14.29: MDxHealth: Revenue (by Region), 2018-2020
- Figure 14.30: MDxHealth: R&D Expenditure, 2018-2020
- Figure 14.31: MDxHealth: SWOT Analysis
- Figure 14.32: Merck KGaA: Product Portfolio
- Figure 14.33: Merck KGaA: Overall Financials, 2018-2020
- Figure 14.34: Merck KGaA: Revenue (by Segment), 2018-2020
- Figure 14.35: Merck KGaA: Revenue (by Region), 2018-2020
- Figure 14.36: Merck KGaA: R&D Expenditure, 2018-2020
- Figure 14.37: Merck KGaA: SWOT Analysis
- Figure 14.38: MutantDx: Product Portfolio
- Figure 14.39: MutantDx: SWOT Analysis
- Figure 14.40: Norgen Biotek Corp: Product Portfolio
- Figure 14.41: Norgen Biotek Corp: SWOT Analysis
- Figure 14.42: Nucleix Ltd.: Product Portfolio
- Figure 14.43: Nucleix Ltd.: SWOT Analysis
- Figure 14.44: Oasis Diagnostics Corporation: Product Portfolio
- Figure 14.45: Oasis Diagnostics Corporation: SWOT Analysis
- Figure 14.46: OraSure Technologies, Inc.: Product Portfolio
- Figure 14.47: OraSure Technologies, Inc.: Overall Financials, 2018-2020
- Figure 14.48: OraSure Technologies, Inc.: Revenue (by Segment), 2018-2020
- Figure 14.49: OraSure Technologies, Inc.: Revenue (by Molecular Solutions), 2019-2020
- Figure 14.50: OraSure Technologies, Inc.: Revenue (by Region), 2018-2020

- Figure 14.51: OraSure Technologies, Inc.: R&D Expenditure, 2018-2020
- Figure 14.52: OraSure Technologies, Inc.: SWOT Analysis
- Figure 14.53: PerkinElmer Inc.: Product Portfolio
- Figure 14.54: PerkinElmer Inc.: Overall Financials, 2018-2020
- Figure 14.55: PerkinElmer Inc.: Revenue (by Segment), 2018-2020
- Figure 14.56: PerkinElmer Inc.: Revenue (by Region), 2018-2020
- Figure 14.57: PerkinElmer Inc.: R&D Expenditure, 2018-2020
- Figure 14.58: PerkinElmer Inc.: SWOT Analysis
- Figure 14.59: Predicine, Inc.: Service Portfolio
- Figure 14.60: Predicine, Inc.: SWOT Analysis
- Figure 14.61: QIAGEN N.V.: Product Portfolio
- Figure 14.62: QIAGEN N.V.: Overall Financials, 2018-2020
- Figure 14.63: QIAGEN N.V.: Revenue (by Segment), 2018-2020
- Figure 14.64: QIAGEN N.V.: Revenue (by Region), 2018-2020
- Figure 14.65: QIAGEN N.V.: R&D Expenditure, 2018-2020
- Figure 14.66: QIAGEN N.V.: SWOT Analysis
- Figure 14.67: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 14.68: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
- Figure 14.69: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
- Figure 14.70: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
- Figure 14.71: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
- Figure 14.72: Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 14.73: Zymo Research Corporation: Product Portfolio
- Figure 14.74: Zymo Research Corporation: SWOT Analysis

I would like to order

Product name: Global Non-Invasive Liquid Biopsy Market: Focus on Offering, Sample, Application, Technology, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

Product link: <https://marketpublishers.com/r/GEE644E307D4EN.html>

Price: US\$ 5,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEE644E307D4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970